Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib

Main Article Content

Leonardo Gomes da Fonseca *
Romualdo Barroso-Sousa
Jorge Sabbaga
Paulo Marcelo Hoff
(*) Corresponding Author:
Leonardo Gomes da Fonseca |


A 55-year old man was treated with sunitinib 50 mg/day for 4 weeks on and 2 weeks off, as a first-line therapy for metastatic renal cell carcinoma. During the fourth week of the first cycle, he was admitted to the Emergency Department with abdominal pain and vomiting. Acute acalculous cholecystitis was diagnosed. Sunitnib-associated cholecystitis is a rare adverse event previously reported in few cases. The mechanism behind this complication is not fully understood, although vascular endothelial dysfunction may play a role. The use of this drug is expanding in clinical oncology, and physicians should be aware of this life-threating adverse event.

Downloads month by month


Download data is not yet available.

Article Details